[go: up one dir, main page]

GB202214132D0 - CLL1 binding molecules - Google Patents

CLL1 binding molecules

Info

Publication number
GB202214132D0
GB202214132D0 GBGB2214132.9A GB202214132A GB202214132D0 GB 202214132 D0 GB202214132 D0 GB 202214132D0 GB 202214132 A GB202214132 A GB 202214132A GB 202214132 D0 GB202214132 D0 GB 202214132D0
Authority
GB
United Kingdom
Prior art keywords
binding molecules
cll1
cll1 binding
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2214132.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coding Bio Ltd
Original Assignee
Coding Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coding Bio Ltd filed Critical Coding Bio Ltd
Priority to GBGB2214132.9A priority Critical patent/GB202214132D0/en
Publication of GB202214132D0 publication Critical patent/GB202214132D0/en
Priority to PCT/GB2023/052497 priority patent/WO2024069165A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
GBGB2214132.9A 2022-09-27 2022-09-27 CLL1 binding molecules Ceased GB202214132D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2214132.9A GB202214132D0 (en) 2022-09-27 2022-09-27 CLL1 binding molecules
PCT/GB2023/052497 WO2024069165A1 (en) 2022-09-27 2023-09-26 Cll1 binding molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2214132.9A GB202214132D0 (en) 2022-09-27 2022-09-27 CLL1 binding molecules

Publications (1)

Publication Number Publication Date
GB202214132D0 true GB202214132D0 (en) 2022-11-09

Family

ID=83978555

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2214132.9A Ceased GB202214132D0 (en) 2022-09-27 2022-09-27 CLL1 binding molecules

Country Status (2)

Country Link
GB (1) GB202214132D0 (en)
WO (1) WO2024069165A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025215183A1 (en) * 2024-04-11 2025-10-16 Universität Heidelberg Anti-cll1 binding agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2008157379A2 (en) 2007-06-21 2008-12-24 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR20110104032A (en) 2008-12-19 2011-09-21 마크로제닉스, 인크. Covalently Bonded Diabodies and Their Uses
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
SG10201705787VA (en) * 2012-09-27 2017-08-30 Merus Nv BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
TWI718992B (en) 2014-07-21 2021-02-21 瑞士商諾華公司 Treatment of cancer using a cll-1 chimeric antigen receptor
US10669337B2 (en) * 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
BR112017004802A2 (en) * 2014-09-12 2017-12-12 Genentech Inc anti-cll-1 and immunoconjugate antibodies
PE20200400A1 (en) 2016-04-01 2020-02-26 Kite Pharma Inc CHEMERICAL RECEPTORS AND METHODS OF USE OF THE SAME
EP3875484A4 (en) * 2018-10-26 2022-07-20 CRAGE medical Co., Limited ANTIBODY TARGETING CLL1 AND ITS USE
AU2021267023A1 (en) * 2020-05-06 2022-12-01 Dragonfly Therapeutics, Inc. Antibodies targeting CLEC12A and use thereof
CN113234169B (en) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 Targeting CLL1 chimeric antigen receptor and its application
EP4281566A1 (en) 2021-01-20 2023-11-29 Coding Bio Limited Methods for high throughput screening of chimeric antigen receptors

Also Published As

Publication number Publication date
WO2024069165A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
GB202006629D0 (en) Specific binding molecules
GB201901306D0 (en) Multi-domain binding molecules
GB201901305D0 (en) Specific binding molecules
GB201811408D0 (en) CD137 Binding Molecules
IL287555A (en) Binding molecules
GB201915282D0 (en) Specific binding molecules
IL308394A (en) Bispecific binding molecule
IL288561A (en) Anti-gal9 immune-inhibiting binding molecules
GB202306345D0 (en) Binding molecules
GB202010329D0 (en) Specific binding molecules
GB202214132D0 (en) CLL1 binding molecules
SG11202113222PA (en) Activating anti-gal9 binding molecules
GB201906118D0 (en) Anti-LAG-3 binding molecules
IL318930A (en) Multi-domain binding molecules
IL318933A (en) Multi-domain binding molecules
GB201904328D0 (en) Specific binding molecules
GB202210680D0 (en) Binding molecules targeting il-35r
GB202315963D0 (en) Binding molecules
GB202314107D0 (en) Binding molecules
GB202312621D0 (en) Binding molecules
GB202311267D0 (en) Binding molecules
GB202209573D0 (en) Binding molecules
GB202110360D0 (en) Binding molecules
GB202100737D0 (en) Binding molecules
GB202016611D0 (en) Binding molecules

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)